SCHEMBL4649145

SCHEMBL4649145

OC(C#Cc1ccc(N2CCOCC2)cc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
GRM5 P41594 1/20 0.48
ACP1 P24666 1/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 7/20 0.43
ACACB O00763 1/20 0.43
MAPT P10636 5/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
MAPK1 P28482 2/20 0.42
HTT P42858 2/20 0.41
CYP1A2 P05177 1/20 0.41
AR P10275 1/20 0.40
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8358624 0.94 GRM5 (0.51) LMNAGRM5ACP1PKMTSHR
SCHEMBL3951909 0.88 ALDH1A1 (0.50) LMNAPKMTSHRMEN1KMT2A
SCHEMBL4649159 0.87 ALDH1A1 (0.51) LMNAPKMTSHRMEN1KMT2A
SCHEMBL4649497 0.86 KDM4E (0.46) LMNAGRM5MEN1KMT2AALDH1A1
SCHEMBL163754 0.83 MAPT (0.49) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL1821168 0.83 MAPT (0.49) MEN1KMT2AALDH1A1MAPTRAB9A
SCHEMBL3996471 0.82 ALDH1A1 (0.47) LMNAGRM5PKMTSHRMEN1
SCHEMBL8350349 0.81 ALDH1A1 (0.48) LMNAGRM5PKMTSHRKMT2A
SCHEMBL1819239 0.80 MAPT (0.41) MEN1KMT2AALDH1A1ACACBMAPT
SCHEMBL1820200 0.78 ACACB (0.38) LMNAALDH1A1ACACBMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313996-A1 INDENONAPHTHOPYRANS HAVING TRIALKYLSILYL AND ETHYLENICALLY UNSATURATED GROUPS Transitions Optical, Ltd. (IE) 2024-02-07 EP disclosed
CN-107253943-B Photochromic compounds and compositions 光学转变公司 2022-05-17 CN disclosed
EP-2651912-B1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2018-10-03 EP disclosed
US-9034219-B2 Photochromic compounds and compositions TRANSITIONS OPTICAL, INC. (US) 2015-05-19 US disclosed
EP-2651914-B1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL INC (US) 2015-05-13 EP disclosed
EP-2651914-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS Transitions Optical, Inc. (US) 2013-10-23 EP disclosed
WO-2012082999-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 WO disclosed
US-20120156521-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS TRANSITIONS OPTICAL, INC. (US) 2012-06-21 US disclosed
EP-1963896-A1 PHOTOCHROMIC MATERIALS HAVING ELECTRON-WITHDRAWING SUBSTITUENTS TRANSITIONS OPTICAL, INC. (US) 2008-09-03 EP disclosed
EP-1872159-A1 OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS Johnson and Johnson Vision Care, Inc. (US) 2008-01-02 EP disclosed
EP-1866699-A1 PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS TRANSITIONS OPTICAL, INC. (US) 2007-12-19 EP disclosed
WO-2007073462-A1 PHOTOCHROMIC MATERIALS HAVING ELECTRON-WITHDRAWING SUBSTITUENTS TRANSITIONS OPTICAL, INC. (US) 2007-06-28 WO disclosed
WO-2006110520-A1 OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS JOHNSON & JOHNSON VISION CARE, INC. (US) 2006-10-19 WO disclosed
WO-2006110219-A1 PHOTOCHROMIC MATERIALS WITH REACTIVE SUBSTITUENTS TRANSITIONS OPTICAL, INC. (US) 2006-10-19 WO disclosed
EP-1265885-A2 HYDROXYLATED/CARBOXYLATED NAPHTHOPYRANS TRANSITIONS OPTICAL, INC. (US) 2002-12-18 EP disclosed
WO-2001070719-A2 HYDROXYLATED/CARBOXYLATED NAPHTHOPYRANS TRANSITIONS OPTICAL, INC. (US) 2001-09-27 WO disclosed
EP-1097156-A2 PHTOCHROMIC BENZOPYRANO-FUSED NAPHTHOPYRANS TRANSITIONS OPTICAL, INC. (US) 2001-05-09 EP disclosed
WO-2000002884-A2 PHOTOCHROMIC BENZOPYRANO-FUSED NAPHTHOPYRANS TRANSITIONS OPTICAL, INC. (US) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120156521-A1 PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS CRY2, CRY1, PPOX LMNA 657/4885GRM5 3559/4885ACP1 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.